The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up

被引:48
|
作者
Maffey-Steffan, Johanna [1 ]
Scarpa, Lorenza [1 ]
Svirydenka, Anna [1 ]
Bernhard, Nilica [1 ]
Mair, Christian [1 ]
Buxbaum, Sabine [1 ]
Bektic, Jasmin [2 ]
von Guggenberg, Elisabeth [1 ]
Uprimny, Christian [1 ]
Horninger, Wolfgang [2 ]
Virgolini, Irene [1 ]
机构
[1] Med Univ Innsbruck, Dept Nucl Med, Anichstr 35, A-6020 Innsbruck, Austria
[2] Med Univ Innsbruck, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria
关键词
Lu-177-PSMA-617; Metastasized castration; resistant prostate cancer; Dosimetry; Post-therapy whole-body scintigraphy; Ga-68-PSMA-11; Theragnostic concept; LU-177-PSMA-617 RADIOLIGAND THERAPY; SURVIVAL; CRITERIA; CYCLES; RECIST; SAFETY; PET/CT; TUMOR;
D O I
10.1007/s00259-019-04583-2
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction A new therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) of heavily pre-treated patients lies in Lu-177-PSMA-617 radioligand therapy. Methods On the basis of PSMA-targeted Ga-68-PSMA-11 PET/CT, 32 consecutive mCRPC patients were selected for Lu-177-PSMA-617 therapy (6 GBq/cycle, 2 to 6 cycles, 6-10 weeks apart) and followed until death. Post-therapy whole-body (WB) dosimetry and Ga-68-PSMA-11 PET/CT data were compared and related to progression free and overall survival. Results Lu-177-PSMA-617 dosimetry after the first cycle indicated high tumor doses for skeletal (4.01 +/- 2.64; range 1.10-13.00 Gy/GBq), lymph node (3.12 +/- 2.07; range 0.70-8.70 Gy/GBq), and liver (2.97 +/- 1.38; range 0.76-5.00 Gy/GBq) metastases whereas the dose for tissues/organs was acceptable in all patients for an intention-to-treat activity of 24 GBq. Any PSA decrease after the first cycle was found in 23/32 (72%), after the second cycle in 22/32 (69%), after the third cycle in 16/28 (57%), and after the fourth cycle in 8/18 (44%) patients. Post-therapy 24 h WB scintigraphy showed decreased tumor-to-background ratios in 24/32 (75%) after the first therapy cycle, after the second cycle in 17/29 (59%), and after the third cycle in 13/21 (62%) patients. The median PFS was 7 months and the median OS 12 months. In the group of PSA responders (n = 22) the median OS was 17 months versus 11 months in the group of non-responders (n = 10), p < 0.05. Decreasing SUVmax values were found for parotid (15.93 +/- 6.23 versus 12.33 +/- 4.07) and submandibular glands (17.65 +/- 7.34 versus 13.12 +/- 4.62) following treatment, along with transient (n = 6) or permanent (n = 2) xerostomia in 8/32 (25%) patients. In 3/32 patients, nephrotoxicity changed from Grade 2 to 3, whereas neither Grade 4 nephrotoxicity nor hematotoxicity was found. In most patients a good agreement was observed for the visual interpretation of the tracer accumulation between 24 h WB and PET/CT scans. However, no significance could be calculated for baseline-absorbed tumor doses and SUVmax values of tumor lesions. 5/32 (16%) patients showed a mixed response pattern, which resulted in disease progression over time. Conclusion Serial PSA measurements and post-therapy 24 h WB scintigraphy seems to allow a sufficiently accurate follow-up of Lu-177-PSMA-617-treated mCRPC patients whereas Ga-68-PSMA-11 PET/CT should be performed for patient selection and final response assessment.
引用
收藏
页码:695 / 712
页数:18
相关论文
共 45 条
  • [41] Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer
    Violet, John
    Sandhu, Shahneen
    Iravani, Amir
    Ferdinandus, Justin
    Sue-Ping Thang
    Kong, Grace
    Kumar, Aravind Ravi
    Akhurst, Tim
    Pattison, David
    Beaulieu, Alexis
    Mooi, Jennifer
    Tran, Ben
    Guo, Christina
    Kalff, Victor
    Murphy, Declan G.
    Jackson, Price
    Eu, Peter
    Scalzo, Mark
    Williams, Scott G.
    Hicks, Rod J.
    Hofman, Michael S.
    Tran, Ben
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (06) : 857 - 865
  • [42] Serial whole-body 177Lu-SPECT quantitation for response assessment in metastatic, castration-resistant prostate cancer within a phase 1/2 trial of 177LuPSMA-617 plus NOX66 (LuPIN)
    Pathmanandavel, Sarennya
    Crumbaker, Megan
    Nguyen, Andrew
    Yam, Andrew
    Wilson, Peter
    Niman, Remy
    Ayers, Maria
    Sharma, Shikha
    Hickey, Adam
    Eu, Peter
    Eslick, Enid
    Marquis, Harry
    Stockler, Martin
    Martin, Andrew
    Joshua, Anthony
    Emmett, Louise
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63
  • [43] Comparison of quantitative whole body PET parameters on [68Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prostate cancer
    Ayati, Narjess
    Mcintosh, Lachlan
    Buteau, James
    Alipour, Ramin
    Pudis, Michal
    Daw, Nicholas
    Jackson, Price
    Hofman, Michael S.
    CANCER IMAGING, 2024, 24 (01)
  • [44] The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/ CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)
    Pathmanandavel, Sarennya
    Crumbaker, Megan
    Nguyen, Andrew
    Yam, Andrew O.
    Wilson, Peter
    Niman, Remy
    Ayers, Maria
    Sharma, Shikha
    Eu, Peter
    Martin, Andrew J.
    Stockler, Martin R.
    Joshua, Anthony M.
    Emmett, Louise
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 69 - 74
  • [45] Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial
    Gafita, Andrei
    Martin, Andrew J.
    Emmett, Louise
    Eiber, Matthias
    Iravani, Amir
    Fendler, Wolfgang P.
    Buteau, James
    Sandhu, Shahneen
    Azad, Arun A.
    Herrmann, Ken
    Stockler, Martin R.
    Davis, Ian D.
    Hofman, Michael S.
    EUROPEAN UROLOGY ONCOLOGY, 2025, 8 (01): : 21 - 28